Rituximab-Treated Patients Have a Poor Response to Influenza Vaccination

[1]  A. Tierens,et al.  Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. , 2011, Blood.

[2]  H. Ochs,et al.  Effect of rituximab on human in vivo antibody immune responses. , 2011, The Journal of allergy and clinical immunology.

[3]  E. Zackai,et al.  A Prospective Study of Influenza Vaccination and a Comparison of Immunologic Parameters in Children and Adults with Chromosome 22q11.2 Deletion Syndrome (DiGeorge Syndrome/Velocardiofacial Syndrome) , 2011, Journal of Clinical Immunology.

[4]  G. Air,et al.  Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features. , 2011, Arthritis and rheumatism.

[5]  I. Grotto,et al.  Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases , 2011, Arthritis care & research.

[6]  F. Marincola,et al.  Impaired Response to Influenza Vaccine Associated with Persistent Memory B Cell Depletion in Non-Hodgkin’s Lymphoma Patients Treated with Rituximab-Containing Regimens , 2011, The Journal of Immunology.

[7]  E. Mendelson,et al.  The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. , 2011, Vaccine.

[8]  B. Afessa,et al.  Hospitalized patients with 2009 H1N1 influenza infection: the Mayo Clinic experience. , 2010, Mayo Clinic proceedings.

[9]  A. Jawad,et al.  The Efficacy of Influenza Vaccination in a Pediatric Oncology Population , 2010, Journal of pediatric hematology/oncology.

[10]  Lyn Finelli,et al.  Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. , 2009, The New England journal of medicine.

[11]  E. Janoff,et al.  Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. , 2009, The Lancet. Infectious diseases.

[12]  N. Cox,et al.  Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. , 2009 .

[13]  A. Hoes,et al.  Impact of influenza vaccination on mortality risk among the elderly , 2009, European Respiratory Journal.

[14]  R. Couch.  Seasonal inactivated influenza virus vaccines. , 2008, Vaccine.

[15]  R. Walker,et al.  Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. , 2008, Vaccine.

[16]  W. Gruber,et al.  Correlation of Cellular Immune Responses with Protection against Culture-Confirmed Influenza Virus in Young Children , 2008, Clinical and Vaccine Immunology.

[17]  R. Luqmani,et al.  Mortality in systemic vasculitis: a systematic review. , 2008, Clinical and experimental rheumatology.

[18]  E. L. Luning Prak,et al.  A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery. , 2008, Clinical immunology.

[19]  E. L. Prak,et al.  Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus , 2008, Annals of the rheumatic diseases.

[20]  Ravi S. Misra,et al.  B Cells Promote Resistance to Heterosubtypic Strains of Influenza via Multiple Mechanisms1 , 2008, The Journal of Immunology.

[21]  J. Ablin,et al.  Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response , 2007, Annals of the rheumatic diseases.

[22]  M. Boeckh,et al.  Community Respiratory Virus Infections in Immunocompromised Patients: Hematopoietic Stem Cell and Solid Organ Transplant Recipients, and Individuals with Human Immunodeficiency Virus Infection , 2007, Seminars in respiratory and critical care medicine.

[23]  T. Kuiken,et al.  Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. , 2007, Vaccine.

[24]  Alan D. Roberts,et al.  Priming with Cold-Adapted Influenza A Does Not Prevent Infection but Elicits Long-Lived Protection against Supralethal Challenge with Heterosubtypic Virus1 , 2007, The Journal of Immunology.

[25]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[26]  C. Ewen,et al.  T Cell Responses Are Better Correlates of Vaccine Protection in the Elderly1 , 2006, The Journal of Immunology.

[27]  I. Donatelli,et al.  Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity. , 2006, Vaccine.

[28]  Cecile Viboud,et al.  Mortality due to influenza in the United States--an annualized regression approach using multiple-cause mortality data. , 2006, American journal of epidemiology.

[29]  E. Mendelson,et al.  Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNFα blockers , 2005, Annals of the rheumatic diseases.

[30]  Keiji Fukuda,et al.  Influenza-associated hospitalizations in the United States. , 2004, JAMA.

[31]  G. Lüchters,et al.  Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? , 2004, Virus research.

[32]  R. Belshe,et al.  Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination , 2004, The Pediatric infectious disease journal.

[33]  F. Ruben.  Inactivated influenza virus vaccines in children. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  S. Horning,et al.  Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. , 2004, Blood.

[35]  K. Neuzil,et al.  Cardiopulmonary Hospitalizations During Influenza Season in Adults and Adolescents With Advanced HIV Infection , 2003, Journal of acquired immune deficiency syndromes.

[36]  K. Nichol,et al.  The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. , 2003, Vaccine.

[37]  Keiji Fukuda,et al.  Mortality associated with influenza and respiratory syncytial virus in the United States. , 2003, JAMA.

[38]  S. Gabriel,et al.  Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. , 2002, Arthritis and rheumatism.

[39]  B. Fessler.  Infectious diseases in systemic lupus erythematosus: risk factors, management and prophylaxis. , 2002, Best practice & research. Clinical rheumatology.

[40]  J. A. Misplon,et al.  Heterosubtypic Immunity to Influenza A Virus in Mice Lacking IgA, All Ig, NKT Cells, or γδ T Cells1 , 2001, The Journal of Immunology.

[41]  K. Neuzil,et al.  The burden of influenza illness in children with asthma and other chronic medical conditions. , 2000, The Journal of pediatrics.

[42]  L. Krilov,et al.  Influenza and respiratory syncytial virus. Update on infection, management, and prevention. , 2000, Pediatric clinics of North America.

[43]  E F Mitchel,et al.  The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. , 2000, The New England journal of medicine.

[44]  G. Hughes,et al.  Morbidity and mortality in systemic lupus erythematosus during a 5-year period - A multicenter prospective study of 1,000 patients , 1999 .

[45]  K. Neuzil,et al.  Influenza-associated morbidity and mortality in young and middle-aged women. , 1999, JAMA.

[46]  P. Doherty,et al.  Effector CD4+ and CD8+ T‐cell mechanisms in the control of respiratory virus infections , 1997, Immunological reviews.

[47]  P. Stevenson,et al.  Protection against influenza virus encephalitis by adoptive lymphocyte transfer. , 1997, Virology.

[48]  P. Stevenson,et al.  Protection against lethal influenza virus encephalitis by intranasally primed CD8+ memory T cells. , 1996, Journal of immunology.

[49]  H. Sacks,et al.  The Efficacy of Influenza Vaccine in Elderly Persons , 1995, Annals of Internal Medicine.

[50]  G. Dinant,et al.  The Efficacy of Influenza Vaccination in Elderly Individuals: A Randomized Double-blind Placebo-Controlled Trial , 1994 .

[51]  R. Couch,et al.  High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults , 1994, Journal of clinical microbiology.

[52]  R. Ramphal,et al.  Passive serum antibody causes temporary recovery from influenza virus infection of the nose, trachea and lung of nude mice. , 1988, Immunology.

[53]  R. Day,et al.  The oncogenicity of chlorambucil in rheumatoid arthritis. , 1988, British journal of rheumatology.

[54]  J. Yewdell,et al.  Monoclonal antibodies detect different forms of influenza virus hemagglutinin during viral penetration and biosynthesis , 1985, Journal of virology.

[55]  P. Doherty,et al.  Breakdown of the blood-cerebrospinal fluid barrier to immunoglobulin in mice injected intracerebrally with a neurotropic influenza A virus Post-exposure treatment with monoclonal antibody promotes recovery , 1981, Journal of Neuroimmunology.

[56]  J. Virelizier,et al.  Host defenses against influenza virus: the role of anti-hemagglutinin antibody. , 1975, Journal of immunology.

[57]  R. Panush.  Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study , 2012 .

[58]  J. Kaldor,et al.  Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[59]  S. Agarwal,et al.  Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. , 2010, Arthritis and rheumatism.

[60]  C. Kallenberg,et al.  Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. , 2010, Arthritis and rheumatism.

[61]  Eva K. Lee,et al.  Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans , 2009, Nature Immunology.

[62]  Thomas R. Riley,et al.  A Randomized Double-blind Placebo-controlled Trial , 2004 .

[63]  A. Osterhaus,et al.  Haemagglutination-inhibiting antibody to influenza virus. , 2003, Developments in biologicals.

[64]  J. A. Misplon,et al.  Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or gamma delta T cells. , 2001, Journal of immunology.

[65]  G. Hughes,et al.  Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. , 1999, Medicine.

[66]  W. Roper,et al.  Prevention and control of influenza: Part I, Vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 1994, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[67]  D. Symmons.  Mortality in rheumatoid arthritis. , 1988, British journal of rheumatology.